KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Receivables (2016 - 2025)

Historic Receivables for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $5.7 billion.

  • Regeneron Pharmaceuticals' Receivables fell 757.9% to $5.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.7 billion, marking a year-over-year decrease of 757.9%. This contributed to the annual value of $5.7 billion for FY2025, which is 757.9% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Receivables stood at $5.7 billion for Q4 2025, which was down 757.9% from $5.7 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Receivables ranged from a high of $7.0 billion in Q2 2021 and a low of $4.2 billion during Q1 2021
  • Its 5-year average for Receivables is $5.5 billion, with a median of $5.6 billion in 2023.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 75317.57% in 2021, then plummeted by 2625.1% in 2022.
  • Regeneron Pharmaceuticals' Receivables (Quarter) stood at $6.0 billion in 2021, then decreased by 11.73% to $5.3 billion in 2022, then increased by 6.35% to $5.7 billion in 2023, then increased by 9.61% to $6.2 billion in 2024, then fell by 7.58% to $5.7 billion in 2025.
  • Its last three reported values are $5.7 billion in Q4 2025, $5.7 billion for Q3 2025, and $5.6 billion during Q2 2025.